Ozempic Face Drives Surge in UK Facial Cosmetic Surgery as Breast Reductions Overtake Enlargements

Side effects from weight-loss medications, particularly the phenomenon known as “Ozempic face,” are driving a significant increase in facial cosmetic surgery procedures across the UK, according to newly released data from the British Association of Aesthetic Plastic Surgeons (BAAPS). The data reveals a clear shift in patient demand, with facelifts, brow lifts, and eyelid surgeries rising sharply while traditional procedures like breast augmentations and tummy tucks decline.

Facial procedures are on the rise, with face and neck lifts increasing by 11 percent, brow lifts soaring by 27 percent, and eyelid surgery up by eight percent in the latest reporting period. Surgeons attribute this trend to growing awareness of the side effects of GLP-1 agonist drugs such as Ozempic and Wegovy, which can cause rapid weight loss leading to a gaunt or aged facial appearance—commonly referred to as “Ozempic face”—as the skin loses volume and elasticity faster than it can adapt.

Despite the overall number of cosmetic procedures experiencing a two percent drop from the previous year, with 26,840 procedures performed in 2025, certain surgeries are bucking the trend. Breast augmentation remains the most popular form of cosmetic surgery in the UK, with 4,761 procedures in 2025, but it is now closely followed by breast reduction surgery at 4,673 procedures—signalling a potential shift in preferences.

Other historically popular procedures have seen sharp declines. Surgeries for abdominoplasties (tummy tucks) and superficial gluteal lipofilling (SGL), a safer alternative to traditional Brazilian butt lifts (BBL), have plummeted, with SGL falling by 38 percent over the past year. Surgeons note that demand for an exaggerated hourglass silhouette may be decreasing, reflecting what they describe as a “growing shift towards comfort and natural proportions.”

The rise in facial procedures is also being influenced by a “new era of openness” on social media, according to former BAAPS president Rajiv Grover, who compiled the audit. This increased transparency has helped change perceptions of facial surgery and reduce stigma around seeking treatment for medication-related side effects.

Clinicians across the UK are reporting more patients presenting with concerns about facial volume loss and accelerated ageing following weight loss from GLP-1 medications. These patients often seek surgical solutions after reaching the limits of what non-surgical treatments can achieve, desiring natural-looking, long-lasting results.

As the use of weight-loss injections continues to grow, so too does the demand for corrective cosmetic procedures. The latest BAAPS data underscores how medical trends are directly shaping aesthetic surgery preferences, with facial rejuvenation now at the forefront of evolving patient priorities in the UK.